New Data Demonstrate siRNA Delivery to Endothelial Cells In Vivo | GenomeWeb

NEW YORK (GenomeWeb) – A team led by researchers from the Massachusetts Institute of Technology this week published a study describing a new type of nanoparticle capable of delivering siRNAs to endothelial cells, while dodging hepatocytes and immune cells, at doses far lower than previously required.

The siRNA-loaded nanoparticles were also able to mediate highly durable non-liver gene silencing, further opening the door for RNAi as a therapeutic modality in diseases such as cancer and emphysema.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.